Abstract
Amino acid transport is an attractive target for oncologic imaging. Despite a high demand of cancer cells for cationic amino acids, their potential as PET probes remains unexplored. Arginine, in particular, is involved in a number of biosynthetic pathways that significantly influence carcinogenesis and tumor biology. Cationic amino acids are transported by several cationic transport systems including, ATB0,+ (SLC6A14), which is upregulated in certain human cancers including cervical, colorectal and estrogen receptor-positive breast cancer. In this work, we report the synthesis and preliminary biological evaluation of a new cationic analog of the clinically used PET tumor imaging agent O-(2-[18F]fluroethyl)-l-tyrosine ([18F]FET), namely O-2((2-[18F]fluoroethyl)methylamino)ethyltyrosine ([18F]FEMAET). Reference compound and precursor were prepared by multi-step approaches. Radiosynthesis was achieved by no-carrier-added nucleophilic [18F]fluorination in 16–20 % decay-corrected yields with radiochemical purity >99 %. The new tracer showed good stability in vitro and in vivo. Cell uptake assays demonstrated that FEMAET and [18F]FEMAET accumulate in prostate cancer (PC-3) and small cell lung cancer cells (NCI-H69), with an energy-dependent mechanism. Small animal PET imaging with NCI-H69 xenograft-bearing mice revealed good tumor visualization comparable to [18F]FET and low brain uptake, indicating negligible transport across the blood–brain barrier. In conclusion, the non-natural cationic amino acid PET probe [18F]FEMAET accumulates in cancer cells in vitro and in vivo with possible involvement of ATB0,+.
Similar content being viewed by others
Abbreviations
- [18F]FDG:
-
2-[18F]fluoro-2-deoxy-d-glucose
- mTOR:
-
Mammalian target of rapamycin
- LAT1:
-
System L amino acid transporter
- [18F]FET:
-
O-(2-[18F]fluroethyl)-l-tyrosine
- CAT:
-
Cationic amino acid transporter family
- NO:
-
Nitric oxide
- [18F]AFETP:
-
(S)-2-amino-3-[1-(2-[18F]fluoroethyl)-1H-[1,2,3]triazol-4-yl]propanoic acid
- [18F]FEMAET:
-
O-2((2-[18F]fluoroethyl)methylamino)ethyltyrosine
- DEAD:
-
Diethyl azodicarboxylate
- KCN:
-
Potassium cyanide
- DIPEA:
-
Diisopropylethylamine
- DAST:
-
Diethylaminosulfurtrifluoride
- CBr4 :
-
Carbon tetrabromide
- PPh3 :
-
Triphenylphosphine
- [18F]FDOPA:
-
l-3,4-Dihydroxy-6-[18F]fluorophenylalanine
- EBSS:
-
EARLE balanced salt solution
References
Bacherikov VA, Chou TC, Dong HJ, Zhang X, Chen CH, Lin YW, Tsai TJ, Lee RZ, Liu LF, Su TL (2005) Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: synthesis and biological activity. Bioorg Med Chem 13(12):3993–4006. doi:10.1016/j.bmc.2005.03.057
Beugnet A, Tee AR, Taylor PM, Proud CG (2003) Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability (vol 372, pg 555, 2003). Biochem J 373:999
Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM (1999) Selective expression of the large neutral amino acid transporter at the blood-brain barrier. P Natl Acad Sci USA 96(21):12079–12084. doi:10.1073/pnas.96.21.12079
Boeckman RK Jr, Miller Y, Savage D, Summerton JE (2011) Total synthesis of a possible specific and effective acid-targeted cancer diagnostic, a camphor derived bis-N-oxide dimer. Tetrahedron Lett 52(17):2243–2245
Busch H, Davis JR, Honig GR, Anderson DC, Nair PV, Nyhan WL (1959) Uptake of a variety of amino acids into nuclear proteins of tumors and other tissues. Cancer Res 19(10):1030–1039
Closs EI (2002) Expression, regulation and function of carrier proteins for cationic amino acids. Curr Opin Nephrol Hy 11(1):99–107. doi:10.1097/00041552-200201000-00015
Closs EI, Boissel JP, Habermeier A, Rotmann A (2006) Structure and function of cationic amino acid transporters (CATs). J Membrane Biol 213(2):67–77. doi:10.1007/s00232-006-0875-7
Comer JEA (2007) Ionization constants and ionization profiles. In: Testa B, Van de Waterbeemd H (eds) Comprehensive Medicinal Chemistry II, vol 5. Elsevier, Amsterdam, pp 357–397
Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA (2004) Incidence and distribution of argininosuccinate synthetase deficiency in human cancers—a method for identifying cancers sensitive to arginine deprivation. Cancer 100(4):826–833. doi:10.1002/Cncr.20057
Fuchs BC, Bode BP (2005) Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 15(4):254–266. doi:10.1016/j.semcancer.2005.04.005
Ganapathy V, Thangaraju M, Prasad PD (2009) Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Therapeut 121(1):29–40. doi:10.1016/j.pharmthera.2008.09.005
Gupta N, Miyauchi S, Martindale RG, Herdman AV, Podolsky R, Miyake K, Mager S, Prasad PD, Ganapathy ME, Ganapathy V (2005) Upregulation of the amino acid transporter ATB(0,+) (SLC6A14) in colorectal cancer and metastasis in humans. Bba Mol Basis Dis 1741(1–2):215–223. doi:10.1016/j.bbadis.2005.04.002
Gupta N, Prasad PD, Ghamande S, Moore-Martin P, Herdman AV, Martindale RG, Podolsky R, Mager S, Ganapathy ME, Ganapathy V (2006) Up-regulation of the amino acid transporter ATB(0, +) (SLC6A14) in carcinoma of the cervix. Gynecol Oncol 100(1):8–13. doi:10.1016/j.ygyno.2005.08.016
Hawkins RA, O’Kane RL, Simpson IA, Vina JR (2006) Structure of the blood-brain barrier and its role in the transport of amino acids. J Nutr 136(1):218s–226s
Herzig J, Nudelman A, Gottlieb HE, Fischer B (1986) Studies in sugar chemistry 2. A simple method for O-deacylation of polyacylated sugars. J Org Chem 51(5):727–730
Honer M, Bruhlmeier M, Missimer J, Schubiger AP, Ametamey SM (2004) Dynamic imaging of striatal D-2 receptors in mice using quad-HIDAC PET. J Nucl Med 45(3):464–470
Kaim AH, Weber B, Kurrer MO, Westera G, Schweitzer A, Gottschalk J, von Schulthess GK, Buck A (2002) F-18-FDG and F-18-FET uptake in experimental soft tissue infection. Eur J Nucl Med Mol I 29(5):648–654. doi:10.1007/s00259-002-0780-y
Kanai Y, Fukasawa Y, Cha SH, Segawa H, Chairoungdua A, Kim DK, Matsuo H, Kim JY, Miyamoto K, Takeda E, Endou H (2000) Transport properties of a system y(+)L neutral and basic amino acid transporter—insights into the mechanisms of substrate recognition. J Biol Chem 275(27):20787–20793. doi:10.1074/jbc.M000634200
Karunakaran S, Ramachandran S, Coothankandaswamy V, Elangovan S, Babu E, Periyasamy-Thandavan S, Gurav A, Gnanaprakasam JP, Singh N, Schoenlein PV, Prasad PD, Thangaraju M, Ganapathy V (2011) SLC6A14 (ATB(0, +)) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer. J Biol Chem 286(36):31830–31838. doi:10.1074/jbc.M111.229518
Kim DK, Ahn SG, Park JC, Kanai Y, Endou H, Yoon JH (2004) Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in oral squamous cell carcinoma and its precusor lesions. Anticancer Res 24(3A):1671–1675
Kobayashi K, Ohnishi A, Promsuk J, Shimizu S, Kanai Y, Shiokawa Y, Nagane M (2008) Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells. Neurosurgery 62(2):493–503. doi:10.1227/01.Neu.0000255470.75752.02
Koopmans KP, Neels ON, Kema IP, Elsinga PH, Links TP, de Vries EGE, Jager PL (2009) Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Oncol Hemat 71(3):199–213. doi:10.1016/j.critrevonc.2009.02.009
Krämer SD, Mu L, Müller A, Keller C, Kuznetsova OF, Schweinsberg C, Franck D, Müller C, Ross TL, Schibli R, Ametamey SM (2012) 5-(2-18F-fluoroethoxy)-l-tryptophan as a substrate of system L transport for tumor imaging by PET. J Nucl Med 53(3):434–442. doi:10.2967/jnumed.111.096289
Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D, Coenen HH, Pauleit D (2006) O-(2-[(18)F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 33(3):287–294. doi:10.1016/j.nuemedbio.2006.01.002
Lee TS, Ahn SH, Moon BS, Chun KS, Kang JH, Cheon GJ, Choi CW, Lim SM (2009) Comparison of F-18-FDG, F-18-FET and F-18-FLT for differentiation between tumor and inflammation in rats. Nucl Med Biol 36(6):681–686. doi:10.1016/j.nucmedbio.2009.03.009
Lind DS (2004) Arginine and cancer. J Nutr 134(10):2837s–2841s
McConathy J, Goodman MM (2008) Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography. Cancer Metast Rev 27(4):555–573. doi:10.1007/s10555-008-9154-7
McConathy J, Zhou D, Shockley SE, Jones LA, Griffin EA, Lee H, Adams SJ, Mach RH (2010) Click synthesis and biologic evaluation of (R)- and (S)-2-amino-3-[1-(2-[F-18]Fluoroethyl)-1H-[1,2,3]Triazol-4-yl]propanoic acid for brain tumor imaging with positron emission tomography. Mol Imaging 9(6):329–342. doi:10.2310/7290.2010.00025
McConathy J, Yu WP, Jarkas N, Seo W, Schuster DM, Goodman MM (2012) Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents. Med Res Rev 32(4):868–905. doi:10.1002/Med.20250
Müller A, Chiotellis A, Keller C, Ametamey SM, Schibli R, Mu L, Krämer SD (2013) Imaging tumour ATB0,+ transport activity by PET with the cationic amino acid O-2((2-[18F]fluoroethyl)methyl-amino)ethyltyrosine. Mol Imaging Biol. doi:10.1007/s11307-013-0711-2
Nakanishi T, Tamai I (2011) Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy. J Pharm Sci Us 100(9):3731–3750. doi:10.1002/Jps.22576
Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, Shima K, Matsuo H, Kanai Y, Endou H (2006) L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 119(3):484–492. doi:10.1002/Ijc.21866
Neels OC, Koopmans KP, Jager PL, Vercauteren L, van Waarde A, Doorduin J, Timmer-Bosscha H, Brouwers AH, de Vries EGE, Dierckx RAJO, Kema IP, Elsinga PH (2008) Manipulation of [C-11]-5-hydroxytryptophan and 6-[F-18]fluoro-3,4-dihydroxy-l-phenylalanine accumulation in neuroendocrine tumor cells. Cancer Res 68(17):7183–7190. doi:10.1158/0008-5472.Can-08-0095
Okuda K, Hirota T, Kingery DA, Nagasawa H (2009) Synthesis of a fluorine-substituted puromycin derivative for Bronsted studies of ribosomal-catalyzed peptide bond formation. J Org Chem 74(6):2609–2612. doi:10.1021/jo802611t
Plathow C, Weber WA (2008) Tumor cell metabolism imaging. J Nucl Med 49:43s–63s. doi:10.2967/jnumed.107.045930
Saier MH, Daniels GA, Boerner P, Lin J (1988) Neutral amino-acid transport-systems in animal-cells—potential targets of oncogene action and regulators of cellular growth. J Membrane Biol 104(1):1–20. doi:10.1007/Bf01871898
Savle PS, Medhekar RA, Kelley EL, May JG, Watkins SF, Fronczek FR, Quinn DM, Gandour RD (1998) Change in the mode of inhibition of acetylcholinesterase by (4-nitrophenyl)sulfonoxyl derivatives of conformationally constrained choline analogues. Chem Res Toxicol 11(1):19–25. doi:10.1021/tx970019o
Schoder H, Larson SM (2004) Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 34(4):274–292. doi:10.1053/j.semnuclmed.2004.06.004
Shreve PD, Anzai Y, Wahl RL (1999) Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19(1):61–77
Silhar P, Pohl R, Votruba I, Hocek M (2005) The first synthesis and cytostatic activity of novel 6-(fluoromethyl)purine bases and nucleosides. Org Biomol Chem 3(16):3001–3007. doi:10.1039/b508122j
Sloan JL, Mager S (1999) Cloning and functional expression of a human Na+ and Cl− dependent neutral and cationic amino acid transporter B0+. J Biol Chem 274(34):23740–23745. doi:10.1074/jbc.274.34.23740
Smith MB, March J (2007) March’s advanced organic chemistry: reactions, mechanisms and structure, 6th edn. Wiley Interscience, Hoboken, pp 355–394
Solingapuram Sai K, Huang CF, Yuan LY, Zhou D, Garbow J, Rich K, Mach R, McConathy J (2011) Comparison of the non-natural amino acid, (S)-[F-18]AFETP, and [F-18]FDG for brain tumor imaging in the mouse DBT model of glioma. J Label Compd Radiopharm 54:S33–S33
Sundin A, Eriksson B, Bergstrom M, Langstrom B, Oberg K, Orlefors H (2004) PET in the diagnosis of neuroendocrine tumors. Ann Ny Acad Sci 1014:246–257. doi:10.1196/annals.1294.027
Sundin A, Garske U, Orlefors H (2007) Nuclear imaging of neuroendocrine tumours. Best Pract Res Cl En 21(1):69–85. doi:10.1016/j.beem.2006.12.003
Tamai S, Masuda H, Ishii Y, Suzuki S, Kanai Y, Endou H (2001) Expression of l-type amino acid transporter 1 in a rat model of liver metastasis: positive correlation with tumor size. Cancer Detect Prev 25(5):439–445
Testa B, Kramer SD (2007) The biochemistry of drug metabolism—an introduction—Part 2. Redox reactions and their enzymes. Chem Biodivers 4(3):257–405. doi:10.1002/cbdv.200790032
Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y (2004) CATs and HATs: the SLC7 family of amino acid transporters. Pflug Arch Eur J Phy 447(5):532–542. doi:10.1007/s00424-003-1086-z
Wagner CA, Lang F, Broer S (2001) Function and structure of heterodimeric amino acid transporters. Am J Physiol Cell Ph 281(4):C1077–C1093
Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M, Stocklin G (1999) Synthesis and radiopharmacology of O-(2-[F-18]fluoroethyl)-l-tyrosine for tumor imaging. J Nucl Med 40(1):205–212
Wise DR, Thompson CB (2010) Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 35(8):427–433. doi:10.1016/j.tibs.2010.05.003
Acknowledgments
We thank Claudia Keller for the excellent technical help in conducting in vitro and in vivo experiments.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chiotellis, A., Müller, A., Weyermann, K. et al. Synthesis and preliminary biological evaluation of O-2((2-[18F]fluoroethyl)methylamino)ethyltyrosine ([18F]FEMAET) as a potential cationic amino acid PET tracer for tumor imaging. Amino Acids 46, 1947–1959 (2014). https://doi.org/10.1007/s00726-014-1754-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-014-1754-7